Compound, evidence, and risk
Ibogaine
Ibogaine is an indole alkaloid studied for substance-use disorders and other possible indications, and it is also associated with serious safety concerns. Potential benefit, study quality, legal status, and cardiac risk have to be read together.
Key Points
- Ibogaine is not FDA-approved as a treatment in the United States and remains Schedule I federally.
- Human evidence includes observational work and early clinical research, with important limitations and selection bias concerns.
- QT/QTc prolongation, arrhythmia risk, drug interactions, screening, and emergency readiness are central safety topics.
- Claims about cures, success rates, or guaranteed withdrawal interruption are checked against study design and source quality.
What Ibogaine Is
Ibogaine is a psychoactive indole alkaloid associated with Tabernanthe iboga and related plants. It is discussed in research on opioid withdrawal, substance-use disorders, traumatic brain injury, neuropsychiatric symptoms, and related mechanisms.
Ibogaine is not the same as whole-plant Iboga, Noribogaine, or newer analogs. Mixing those categories leads readers to mistake a plant tradition, an isolated alkaloid, a metabolite, and a drug-development program for the same thing.
Current Evidence Status
- Opioid-related literature includes observational studies, detoxification reports, and registered clinical research.
- TBI and neuropsychiatric interest grew after a 30-person veteran observational study and later neurophysiology work, but those studies do not establish broad efficacy.
- Recent reviews continue to describe the evidence base as early, limited by small samples, uncontrolled designs, and safety concerns.
Clinical Status
- Ibogaine is not FDA-approved as a treatment in the United States.
- U.S. federal law still places Ibogaine in Schedule I.
- Research interest, state funding, an IND allowance, or clinic marketing does not equal FDA approval.
High-Value Sources
Continue reading
Reader Boundary
Educational reference material only; not medical advice, legal advice, dosing instruction, provider referral, or emergency guidance. Emergency, treatment, and legal decisions belong with qualified professionals and local emergency systems.